A Real-world Study of Characteristics, Treatment Patterns, and Clinical Outcomes Among Lutetium-177 Vipivotide Tetraxetan Treated Patients

计划入组 1,247 人 · 首次发布于 2026 年 3 月 17 日

LuX: Xaluritamig in Participants With Metastatic Castrate Resistant Prostate Cancer and Suboptimal Response to Lutetium 177 Vipivotide Tetraxetan

计划入组 30 人 · 首次发布于 2026 年 7 月 30 日

ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC

计划入组 148 人 · 首次发布于 2023 年 1 月 12 日

Lutetium Lu-177 vipivotide tetraxetan(Pluvicto)

C₄₉H₆₈LuN₉O₁₆

vipivotide tetraxetan

Zalsenertant tetraxetan lutetium Lu-177

Laureate Institute for Brain Research

United States

Aveta Biomics, Inc.

United States

Selcuk University

Turkey

Lutetium Lu 177 Vipivotide Tetraxetan Shows Promise in Prostate Cancer Treatment

FDA Approves Lutetium Lu 177 Vipivotide Tetraxetan for PSMA-Positive Metastatic Castration-Resistant Prostate Cancer

Telix's Illuccix Receives Expanded Approval in Australia and Canada for PSMA-Targeted Therapy Selection